Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

被引：0

作者：

Dietrich, S. ^{[1
]}

Hutchings, M. ^{[2
,3
]}

Avigdor, A. ^{[4
,5
]}

Sureda, A. ^{[6
]}

Terol, M. J. ^{[7
]}

Bosch, F. ^{[8
]}

Corradini, P. ^{[9
,10
]}

Larsen, Stauffer T. ^{[11
]}

Dominguez, Rueda A. ^{[12
]}

Skarbnik, A. ^{[13
]}

Jorgensen, J. ^{[14
]}

Goldschmidt, N. ^{[15
]}

Gurion, R. ^{[16
,17
]}

Zinzani, P. L. ^{[18
,19
]}

Pinto, A. ^{[20
]}

Cordoba, R. ^{[21
]}

Bottos, A. ^{[22
]}

Huang, Z. ^{[23
]}

Simko, S. ^{[24
]}

Relf, J. ^{[25
]}

de L'Etang, Filezac A. ^{[22
]}

Sellam, G. ^{[22
]}

Gritti, G. ^{[26
,27
]}

机构：

[1] Heidelberg Univ Hosp, Clin Hematol, Oncol, Rheumatol, Heidelberg, Germany

[2] Rigshosp, Dept Hematol, Copenhagen, Denmark

[3] Rigshosp, Phase Unit 1, Copenhagen, Denmark

[4] Sheba Med Ctr, Inst Hematol, Ramat Gan, Israel

[5] Tel Aviv Univ, Tel Aviv, Israel

[6] Univ Barcelona, Dept Clin Hematol, Barcelona, Spain

[7] Univ Valencia, Hosp Clin Univ INCLIVA, Dept Hematol, Valencia, Spain

[8] Univ Hosp Vall dHebron, Dept Hematol, Barcelona, Spain

[9] Univ Milan, Milan, Italy

[10] Fdn IRCCS Ist Nazl Tumori, Dept Hematol, Milan, Italy

[11] Odense Univ Hosp, Dept Hematol, Odense, Denmark

[12] Reg & Virgen de la Victoria Univ Hosp, Med Oncol Interctr Unit, Malaga, Spain

[13] Novant Hlth Canc Inst, Lymphoma & CLL Program, Charlotte, NC USA

[14] Aarhus Univ Hosp, Dept Clin Med, Dept Haematol, Aarhus, Denmark

[15] Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel

[16] Rabin Med Ctr, Inst Hematol, Petah Tiqwa, Israel

[17] Tel Aviv Univ, Tel Aviv, Israel

[18] Univ Bologna, IRCCS Azienda Univ Hosp, Bologna Inst Hematol, Bologna, Italy

[19] Univ Bologna, Dept Specialist Diagnost & Expt Med, Bologna, Italy

[20] Natl Canc Inst Fdn G Pascale IRCCS, Dept Hematol, Neapel, Italy

[21] Fdn Jimenez Diaz Univ Hosp, Dept Hematol, Madrid, Spain

[22] F Hoffmann La Roche Ltd, Basel, Switzerland

[23] F Hoffmann La Roche Ltd, Shanghai, Peoples R China

[24] Genentech Inc, San Francisco, CA USA

[25] F Hoffmann La Roche Ltd, Welwyn Garden City, England

[26] Azienda Osped Papa Giovanni XXIII, Hematol Unit, Bergamo, Italy

[27] Azienda Osped Papa Giovanni XXIII, Bone Marrow Transplant Unit, Bergamo, Italy

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P404

引用

页码：209 / 209

页数：1

共 50 条

[31] Real Event Analysis of the Efficacy and Safety of Polatuzumab Vedotin Combination Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Shi, Yuanfei
Xu, Yi
Wang, Jinghan
Zheng, Xiaolong
Li, Xueying
Jin, Jie
Tong, Hongyan
Xie, Wanzhuo
BLOOD, 2023, 142
[32] Epcoritamab plus GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2
Cordoba, Raul
Jorgensen, Judit
Belada, David
Costello, Regis
Trneny, Marek
Vitolo, Umberto
John Lewis, David
Karimi, Yasmin H.
Sureda, Anna
Andre, Marc
Wahlin, Bjorn E.
Lugtenburg, Pieternella J.
Jiang, Tony
Abbas, Aqeel
Song, Yaou
Risum, Malene
Brody, Joshua D.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S468 - S469
[33] Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma
Lu, Tong
Gibiansky, Leonid
Li, Xiaobin
Li, Chunze
Shi, Rong
Agarwal, Priya
Hirata, Jamie
Miles, Dale
Chanu, Pascal
Girish, Sandhya
Jin, Jin Yan
Lu, Dan
LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2905 - 2914
[34] Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma
Varma, Gaurav
Wang, Jacqueline
Diefenbach, Catherine
EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 795 - 803
[35] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
Bell, Jill A.
Cherepanov, Dasha
Revicki, Dennis
Speck, Rebecca M.
Swett, Laura
Stumpo, Kate
Rong, Yuanxin
Gordon, Leo I.
QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
[36] Glofitamab in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL) and ≥2 prior Lines of Therapy: Key Results of the Phase-II Expansion
Hutchings, M.
Dickinson, M.
Carlo-Stella, C.
Morschhauser, F.
Bachy, E.
Corradini, P.
Iacoboni, G.
Khan, C.
Wrobel, T.
Offner, F.
Trneny, M.
Wu, S. -J.
Cartron, G.
Hertzberg, M.
Sureda, A.
Perez-Callejo, D.
Lundberg, L.
Relf, J.
Clark, E.
Humphrey, K.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 50 - 51
[37] Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience
Darcin, Tahir
Yigenoglu, Tugce Nur
Sahin, Derya
Bakirtas, Mehmet
Basci, Semih
Merdin, Alparslan
Yildiz, Jale
Ulu, Bahar Uncu
Tetik, Aysegul
Iskender, Dicle
Cakar, Merih Kizil
Dal, Mehmet Sinan
Altuntas, Fevzi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S249 - S250
[38] A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Hertzberg, Mark
Ku, Matthew
Catalani, Olivier
Althaus, Betsy
Simko, Stephen
Gregory, Gareth P.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
Zhang, Yian
Yuan, Ling
Zhuang, Jingli
Wang, Zhimei
Zhang, Xuejiao
Wang, Weiguang
Liu, Peng
BLOOD, 2023, 142
[40] Patient, Caregiver, and Physician Preferences for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Vukcevic, Mirko
Yung, Mallory
Khan, Mali
Houpt, Bethany
Schnell, Frederick
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S376 - S377

← 1 2 3 4 5 →